SCHEMBL4829005

SCHEMBL4829005

COC(=O)c1ccc(O)cc1NC(=O)c1ccc2ccccc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.63
ALDH1A1 P00352 4/20 0.63
ALOX12 P18054 1/20 0.63
DEGS1 O15121 2/20 0.57
MAPT P10636 3/20 0.56
MEN1 O00255 2/20 0.56
POLB P06746 2/20 0.56
KMT2A Q03164 2/20 0.56
GAA P10253 2/20 0.56
LMNA P02545 1/20 0.56
RAB9A P51151 5/20 0.56
NPC1 O15118 4/20 0.56
TSHR P16473 2/20 0.55
HSD17B10 Q99714 1/20 0.55
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C19 P33261 1/20 0.53
CASP3 P42574 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
ELANE P08246 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19554242 0.91 KDM4E (0.61) KDM4EALDH1A1ALOX12DEGS1MAPT
SCHEMBL21446855 0.89 KDM4E (0.77) KDM4EALDH1A1ALOX12MAPTMEN1
SCHEMBL2275077 0.85 KDM4E (0.66) KDM4EALDH1A1ALOX12MAPTMEN1
SCHEMBL4835334 0.83 TSHR (0.58) KDM4EDEGS1MAPTMEN1POLB
SCHEMBL7949189 0.80 KDM4E (0.61) KDM4EALDH1A1ALOX12MAPTMEN1
SCHEMBL4836146 0.80 GFER (0.64) KDM4EALDH1A1ALOX12DEGS1MAPT
SCHEMBL4825858 0.79 KDM4E (0.52) KDM4EALDH1A1ALOX12MAPTMEN1
SCHEMBL6339040 0.79 ELANE (0.62) KDM4EALDH1A1ALOX12MAPTMEN1
SCHEMBL4800345 0.79 KDM4E (0.59) KDM4EALDH1A1DEGS1MAPTMEN1
SCHEMBL6410492 0.79 TSHR (0.62) KDM4EALDH1A1ALOX12MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293790-A1 SUBSTITUTED ARYL OXIMES WYETH (US) 2008-11-27 US disclosed
US-7420083-B2 Substituted aryloximes WYETH (US) 2008-09-02 US disclosed
EP-1663189-A1 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY)-PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS Wyeth (US) 2006-06-07 EP disclosed
WO-2005030193-A1 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS WYETH (US) 2005-04-07 WO disclosed
US-20050070584-A1 Substituted aryloximes WYETH (US) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070584-A1 Substituted aryloximes AHR, NQO1, AOX1 KDM4E 509/4885ALDH1A1 269/4885ALOX12 219/4885
US-20080293790-A1 SUBSTITUTED ARYL OXIMES HCCS, AOX1, TET2 KDM4E 598/4885ALDH1A1 211/4885ALOX12 562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.